| [1] |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[EB/OL]. [2024-03-12].
URL
|
| [2] |
Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13 (11): 674-690.
|
| [3] |
Sivina E, Blumberga L, Purkalne G, et al. Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer-single hospital experience[J]. Hered Cancer Clin Pract，2023，21(1)：4.
|
| [4] |
Lin Y, Yin W, Yan T, et al. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients[J]. BMC Cancer, 2009, 9：342.
|
| [5] |
丁欣韵，孙洁，陈久安，等．BRCA1/2突变异时性双乳癌首发癌和对侧癌的临床病理特征对比研究[J].肿瘤防治研究，2023，50(7)：652-657.
|
| [6] |
Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11)：674-690.
|
| [7] |
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer[J]. N Engl J Med, 2010, 363 (20): 1938-1948.
|
| [8] |
Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network[J]. Cancer, 2012, 118(22): 5463-5472.
|
| [9] |
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med，2021, 384(16): 1529-1541.
|
| [10] |
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. N Engl J Med, 2022, 387(3): 217-226.
|
| [11] |
National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes[EB/OL].[2024-03-12].
URL
|
| [12] |
Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.
|
| [13] |
Gennari A, André F, Barrios CH, et al. ESMO metastatic breast cancer living guidelines[EB/OL].[2024-03-12].
URL
|
| [14] |
中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志，2023, 33(12): 1092-1187.
|
| [15] |
Emens LA, Adams S, Barrios CH, et al. LBA16 IMpassion130: final OS analysis from the pivotal phase III study of atezolizumab＋ nab-paclitaxel vs placebo＋ nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2020, 31: S1148.
|
| [16] |
Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(8): 994-1004.
|
| [17] |
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J].Lancet, 2020, 396(10 265): 1817-1828.
|
| [18] |
Jiang Z, Ouyang Q, Sun T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial[J]. Nat Med，2024，30(1)：249-256.
|
| [19] |
Szekely B, Bossuyt V, Li X, et al. Immunological differences between primary and metastatic breast cancer[J]. Ann Oncol, 2018, 29(11): 2232-2239.
|
| [20] |
Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs[J]. Nat Rev Clin Oncol, 2022, 19(2): 91-113.
|
| [21] |
Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4＋ CD25＋ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J]. Cancer Immunol Immunother, 2007, 56: 641-648.
|
| [22] |
宋娜娜，方峻．节拍化疗对免疫系统的影响[J].临床内科杂志，2019，36(5)293-296.
|
| [23] |
Mo H, Sun X, Zhai J, et al.Efficacy, safety of toripalimab plus metronomic chemotherapy for Her2-negative metastatic breast cancer[EB/OL].[2024-03-15].
URL
|
| [24] |
Wang L, Geng H, Liu Y, et al. Hot and cold tumors: immunological features and the therapeutic strategies[J]. MedComm, 2023, 4(5): e343.
|
| [25] |
Benoit A, Vogin G, Duhem C, et al. Lighting up the fire in the microenvironment of cold tumors: a major challenge to improve cancer immunotherapy[J]. Cells, 2023, 12(13): 1787.
|
| [26] |
Adams E, Wildiers H, Neven P, et al. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape[J]. ESMO open, 2021, 6(4): 100 204.
|
| [27] |
Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, et al. Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs[J]. Cancer, 2021, 14(1): 154.
|
| [28] |
Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target[J]. Oncotarget, 2018, 9(48): 28 989.
|
| [29] |
Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)[J]. Oncotarget, 2015, 6(26): 22 496.
|
| [30] |
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541.
|
| [31] |
Xu B, Ma F, Wang T, et al. A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments[J]. Int J Cancer, 2023, 152(10): 2134-2144.
|
| [32] |
Fei M, Shusen W, Zhongsheng T, et al. Overall survival results from EVER-132-001, a phase 2b single-arm study of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer[EB/OL].[2024-03-13].
URL
|
| [33] |
Jiangping Y, Xi Y, Jinlan H, et al. Treatment and prognosis of advanced triple-negative breast cancer patients with HER-2-low expression: a 15-year retrospective study[EB/OL].[2024-03-13]
URL
|
| [34] |
Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer[J]. NPJ breast cancer, 2021, 7(1): 137.
|
| [35] |
Xu B, Ma F, Wang S, et al. 22MO efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: subgroup analysis from a phase IIb trial[EB/OL].[2024-03-13].
URL
|
| [36] |
Yin YM, Wu XH, Ouyang Q, et al. Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study. [EB/OL].[2024-01-24].
URL
|
| [37] |
Schmid P, Wysocki PJ, Ma CX, et al. Datopotamab deruxtecan (Dato-DXd)＋ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ib/II study[EB/OL].[2024-01-24].
URL
|
| [38] |
Ma D, Chen SY, Ren JX, et al. Molecular features and functional implications of germline variants in triple-negative breast cancer [J]. J Natl Cancer Inst，2021，113(7)：884-892.
|
| [39] |
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533.
|
| [40] |
Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Eur J Cancer, 2023, 184: 39-47.
|
| [41] |
Rodler E, Sharma P, Barlow WE, et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2023, 24(2): 162-174.
|
| [42] |
邵笛，余天剑，邵志敏．三阴性乳腺癌精准治疗研究进展[J].中国普通外科杂志，2023，32(11)：1629-1638.
|
| [43] |
Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.
|
| [44] |
Grinda T, Antoine A, Jacot W, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort[J]. ESMO open, 2021, 6(3): 100114.
|
| [45] |
Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer cell, 2019, 35(3): 428-440.
|
| [46] |
Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer[J]. Mol Cancer, 2022, 21(1): 86.
|
| [47] |
Jin X, Zhou YF, Ma D, et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer[J]. Nat Genet, 2023, 55(10): 1696-1708.
|
| [48] |
Chen L, Jiang YZ, Wu SY, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial[J]. Clin Cancer Res, 2022, 28(13): 2807-2817.
|
| [49] |
Fan L, Wang ZH, Ma LX, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial[J]. Lancet Oncol, 2024, 25(2): 184-197.
|
| [50] |
Shao ZM, Fan L, Ma LX, et al. FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer [EB/OL].[2024-03-12].
URL
|